Acebutolol - CAS 37517-30-9
Catalog number: 37517-30-9
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C18H28N2O4
Molecular Weight:
336.43
COA:
Inquire
Targets:
Others
Description:
Acebutolol is a synthetic butyranilide derivative with hypotensive and antiarrhythmic activity as a beta blocker for the treatment of hypertension and arrhythmias.
Purity:
≥98%
Appearance:
Crystalline Solid
Synonyms:
N-[3-acetyl-4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]butanamide;
Solubility:
Soluble in DMSO
Storage:
Store at -20 °C
MSDS:
Inquire
Application:
Cardioselective β-adrenergic blocker. Antihypertensive; antianginal; antiarrhythmic (class II).
Quality Standard:
Enterprise standard
Shelf Life:
As supplied, 2 years from the QC date provided on the Certificate of Analysis, when stored properly.
Quantity:
Grams-Kilos
InChIKey:
GOEMGAFJFRBGGG-UHFFFAOYSA-N
InChI:
1S/C18H28N2O4/c1-5-6-18(23)20-14-7-8-17(16(9-14)13(4)21)24-11-15(22)10-19-12(2)3/h7-9,12,15,19,22H,5-6,10-11H2,1-4H3,(H,20,23)
Canonical SMILES:
CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C
1.Aqueous chlorination of acebutolol: kinetics, transformation by-products, and mechanism.
Khalit WN1, Tay KS2. Environ Sci Pollut Res Int. 2016 Feb;23(3):2521-9. doi: 10.1007/s11356-015-5470-y. Epub 2015 Oct 1.
This study investigated the reaction kinetics and the transformation by-products of acebutolol during aqueous chlorination. Acebutolol is one of the commonly used β-blockers for the treatment of cardiovascular diseases. It has been frequently detected in the aquatic environment. In the kinetics study, the second-order rate constant for the reaction between acebutolol and chlorine (k app) was determined at 25 ± 0.1 °C. The degradation of acebutolol by free available chlorine was highly pH dependence. When the pH increased from 6 to 8, it was found that the k app for the reaction between acebutolol and free available chlorine was increased from 1.68 to 11.2 M(-1) min(-1). By comparing with the reported k app values, the reactivity of acebutolol toward free available chlorine was found to be higher than atenolol and metoprolol but lower than nadolol and propranolol. Characterization of the transformation by-products formed during the chlorination of acebutolol was carried out using liquid chromatography-quadrupole time-of-flight high-resolution mass spectrometry.
2.Identification of Radiodegradation Products of Acebutolol and Alprenolol by HPLC/MS/MS.
Ogrodowczyk M1, Dettlaff K, Kachlicki P, Marciniec B. J AOAC Int. 2015 Jan-Feb;98(1):46-50. doi: 10.5740/jaoacint.14-096.
Two therapeutically active compounds from the group of β-blockers, acebutolol (AC) and alprenolol (AL), in solid form were subjected to ionizing radiation emitted by a beam of high energy electrons from an accelerator with a standard sterilization dose of 25 kGy and in higher doses of 50-400 kGy. The effects of irradiation were detected by chromatographic methods (TLC, HPLC) and a hyphenated method (HPLC/MS/MS). No significant changes in the physicochemical properties of both compounds studied irradiated with 25 kGy were noted, but upon irradiation with the highest dose (400 kGy) the loss of AC and AL content determined by HPLC was 2.79 and 9.12%, respectively. The product of AC decomposition and the two products of AL decomposition were separated and identified by HPLC/MS/MS. It has been established that radiodegradation of AC and AL takes place by oxidation, leading to formation of the products of radiolysis, most probably alcohol derivatives of the β-blockers studied.
3.First Case Report of Smith-Magenis Syndrome (SMS) Among the Arab Community in Nazareth: View and Overview.
Nijim Y1, Adawi A, Bisharat B, Bowirrat A. Medicine (Baltimore). 2016 Jan;95(3):e2362. doi: 10.1097/MD.0000000000002362.
Smith-Magenis syndrome (SMS0) is a complex and rare genetic multisystem disorder characterized by a variable pattern of cognitive deficits accompanied by a1 distinctive behavioral phenotype. SMS is characterized by subtle facial dysmorphology, short stature, sleep disturbances, and neurobehavioral abnormalities. Little is known about the manifestation of his unique case among Arab population and its strategic treatment.This study comes to present a case of SMS in an Arab newborn male who was born in spontaneous delivery on June 29, 2015, with tachypnea, tracheomalacia, and mild hypotonia. The newborn was admitted on the Neonatal Intensive Care Unit (NICU), and various laboratory examinations and clinical examinations were performed.Throughout his hospitalization, feeding difficulties appeared and thus a peripheral venous catheter was inserted in the left leg.After 22 days of follow-up and hospitalizations, the patient status improved and he was discharged with recommendations to be in follow up in pediatric outpatient clinic.
4.Development of SPME-LC-MS method for screening of eight beta-blockers and bronchodilators in plasma and urine samples.
Goryński K1, Kiedrowicz A2, Bojko B3. J Pharm Biomed Anal. 2016 Mar 4. pii: S0731-7085(16)30119-4. doi: 10.1016/j.jpba.2016.03.001. [Epub ahead of print]
The current work describes the development and validation of a simple, efficient, and fast method using solid phase microextraction coupled to liquid chromatography-tandem mass spectrometry (SPME-LC-MS/MS) for the concomitant measurement of eight beta-blockers and bronchodilators in plasma and urine. The presented assay enables quantitative determination of acebutolol, atenolol, fenoterol, nadolol, pindolol, procaterol, sotalol, and timolol. In this work, samples were prepared on a high-throughput platform using the 96-well plate format of the thin film solid phase microextraction (TFME) system, and a biocompatible extraction phase made of hydrophilic-lipophilic balance particles. Analytes were separated on a pentafluorophenyl column (100mm×2.1mm, 3μm) by gradient elution using an UPLC Nexera coupled with an LCMS-8060 mass spectrometer. The mobile phase consisted of water-acetonitrile (0.1% formic acid) at a flow rate of 0.4mLmin-1. The linearity of the method was checked within therapeutic blood-plasma concentrations, and shown to adequately reflect typically expected concentrations of future study samples.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 20153-98-4 Dilazep dihydrochloride

Dilazep dihydrochloride
(CAS: 20153-98-4)

The hydrochloride salt form of Dilazep, which has been found to be an angiotensin converting, adenosine reuptake inhibitor and could be used as a cerebral vasod...

CAS 1108-68-5 Cinobufotalin

Cinobufotalin
(CAS: 1108-68-5)

Cinobufotalin is one of the bufadienolides prepared from toad venom. It has anticancer activity.

CAS 108-62-3 Metaldehyde

Metaldehyde
(CAS: 108-62-3)

Metaldehyde, the tetramer form of aldehyde, could be used in the production of other substances and also a pesticide against sorts of gastropods.

CAS 20784-50-3 Isobavachalcone

Isobavachalcone
(CAS: 20784-50-3)

Neuroblastoma, the most common solid extracranial neoplasm in children, originates from embryonic neural crest cells that usually form the sympathetic ganglia a...

CAS 60-56-0 Methimazole

Methimazole
(CAS: 60-56-0)

Methimazole (also known as Tapazole or Thiamazole or MMI) is an antithyroid drug,and part of the thioamide group. Like its counterpart propylthiouracil, a major...

CAS 58546-55-7 Schisantherin B

Schisantherin B
(CAS: 58546-55-7)

Schisantherin B, source from the seeds of Schisandra chinensis (Turcz.) Baill., shows good effect in lowering the serum glutamic-pyruvic transaminase level of t...

CAS 1446321-46-5 GBT-440

GBT-440
(CAS: 1446321-46-5)

GBT-440 is a substituted benzaldehyde compound that can modulate sickle hemoglobin (HbS) for treatment of disorders.

CAS 682741-29-3 HTS01037

HTS01037
(CAS: 682741-29-3)

HTS01037, a high-affinity ligand of adipocyte fatty acid binding protein (A-FABP/aP2) (Ki = 0.67 μM), and is a competitive antagonist of protein-protein interac...

Chemical Structure

CAS 37517-30-9 Acebutolol

Quick Inquiry

Verification code

Featured Items